Voya Investment Management LLC Has $112,000 Stock Holdings in Urogen Pharma $URGN

Voya Investment Management LLC trimmed its position in shares of Urogen Pharma (NASDAQ:URGN) by 10.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,092 shares of the company’s stock after selling 1,153 shares during the period. Voya Investment Management LLC’s holdings in Urogen Pharma were worth $112,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Jane Street Group LLC increased its holdings in Urogen Pharma by 94.3% during the first quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock worth $566,000 after buying an additional 24,839 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Urogen Pharma by 216.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock worth $48,227,000 after buying an additional 2,983,368 shares during the last quarter. Parkman Healthcare Partners LLC increased its holdings in Urogen Pharma by 6.3% during the first quarter. Parkman Healthcare Partners LLC now owns 393,153 shares of the company’s stock worth $4,348,000 after buying an additional 23,292 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Urogen Pharma by 7.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after buying an additional 1,653 shares during the last quarter. Finally, AQR Capital Management LLC increased its holdings in Urogen Pharma by 347.5% during the first quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock worth $1,262,000 after buying an additional 88,577 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on URGN shares. Scotiabank restated an “outperform” rating on shares of Urogen Pharma in a report on Friday, June 13th. Wall Street Zen upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. HC Wainwright decreased their price objective on shares of Urogen Pharma from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Piper Sandler assumed coverage on shares of Urogen Pharma in a report on Monday, August 18th. They issued an “overweight” rating and a $36.00 price objective on the stock. Finally, Guggenheim reiterated a “buy” rating and issued a $30.00 price objective (up from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $32.00.

Urogen Pharma Stock Performance

URGN stock opened at $17.82 on Thursday. The company’s 50-day simple moving average is $19.05 and its 200 day simple moving average is $13.59. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $21.71. The company has a market capitalization of $824.35 million, a PE ratio of -5.37 and a beta of 1.01.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.23). The firm had revenue of $24.22 million for the quarter, compared to analyst estimates of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. On average, analysts forecast that Urogen Pharma will post -3.12 EPS for the current year.

Insider Transactions at Urogen Pharma

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 1,520 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $19.11, for a total transaction of $29,047.20. Following the sale, the general counsel directly owned 43,305 shares in the company, valued at $827,558.55. This represents a 3.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $17.69, for a total transaction of $176,900.00. Following the sale, the insider owned 148,229 shares in the company, valued at $2,622,171.01. The trade was a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 25,062 shares of company stock worth $465,115 over the last quarter. Corporate insiders own 4.70% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.